CMS Energy
CMS
$69.58
-1.02%
CMS Energy Corporation is an energy holding company whose principal subsidiary, Consumers Energy, provides regulated natural gas service to roughly 1.8 million customers and regulated electric service to about 1.9 million customers across Michigan, complemented by NorthStar Clean Energy, a wholesale power and contracted renewables platform. The company is a pure-play regulated utility with a constructive Michigan regulatory compact, distinguishing it as a low-beta, income-oriented operator rather than a growth or merchant-power story. The current investor debate centers on the tension between a 3.15% dividend yield and a stock that has lagged the market badly, with shares down roughly 8% over the past year against a 15.5% gain in the S&P 500, as elevated capital spending, negative free cash flow, and a 2.07x debt-to-equity load weigh on sentiment. Recent news flow has been dominated by routine preferred dividend declarations, underscoring the absence of near-term catalysts and the market's focus on rate-case outcomes, data-center-driven load growth in Michigan, and the company's ability to fund its capital program without diluting equity.…
CMS
CMS Energy
$69.58
Related headlines
Investment Opinion: Should I buy CMS Today?
Rating: Hold. The core thesis is that CMS is a fairly valued, low-beta income utility whose 3.15% dividend and 16.54x forward multiple offer modest total-return potential, but whose negative free cash flow and funding-dependent capital program cap near-term upside; the consensus 'buy' rating and $75.83 average target imply only 10.4% upside, with the $68.00 low target at parity to spot.
Supporting evidence is mixed but leans toward fair value. The forward PE of 16.54x sits mid-band versus the 16x-18x utility peer range, while the 19.81x trailing multiple is near the upper half of the stock's own 14x-22x three-year band. Revenue was flat at -0.49% year over year in Q2 2026, profitability remains solid with a 12.54% trailing net margin and 11.71% ROE, but trailing free cash flow of -$1.91 billion and 2.07x debt-to-equity offset the income appeal. The 3.15% yield at a 61.9% payout is well covered, and the 10.4% implied upside to the consensus target is real but not compelling given the 26.5% spread between the $68 and $86 targets.
The biggest risks that could invalidate the thesis are a negative Michigan rate-case outcome, continued equity issuance diluting per-share earnings (already $362 million in Q2), and a rise in long-term Treasury yields compressing the relative appeal of the dividend. This Hold would upgrade to Buy if the stock establishes a durable base above $70 with a positive rate-case ruling and forward PE compressing below 16x on confirmed EPS growth toward the $5.21 consensus, or downgrade to Sell if revenue growth stays negative and free cash flow deteriorates beyond -$2 billion. On balance, CMS is fairly valued relative to its history and peers — neither a bargain nor expensive — and the risk/reward is balanced rather than compelling until a regulatory catalyst emerges.
Sign up to view all
CMS 12-Month Price Forecast
CMS presents a balanced risk/reward at $68.70: the 16.54x forward multiple is fair rather than cheap, the 3.15% dividend is well covered at a 61.9% payout, and the $75.83 consensus target offers only 10.4% upside with the low target at parity. The funding model is the central constraint — -$1.91 billion in trailing free cash flow, 2.07x debt-to-equity, and $362 million of Q2 equity issuance cap per-share earnings leverage and make the dividend dependent on credit-market access. The one-month momentum reversal of +4.11% versus SPY's +1.22% is constructive but unconfirmed against a -23.62-point one-year relative strength gap. I would upgrade to bullish on a favorable Michigan rate-case ruling combined with forward EPS tracking toward the $5.21 consensus and a confirmed base above $70, and downgrade to bearish if free cash flow deteriorates beyond -$2 billion or the stock breaks below the $62.29 52-week low.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CMS Energy's 12-month outlook, with a consensus price target around $74.69 and implied upside of +7.3% versus the current price.
Average Target
$74.69
0 analysts
Implied Upside
+7.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$68 - $79
Analyst target range
Twelve analysts cover CMS with a consensus recommendation of "buy" and a mean rating of 2.27 on a scale where lower is more bullish, and the average target price of $75.83 implies roughly 10.4% upside from the current $68.70. The distribution of recent institutional actions is more cautious than the headline consensus suggests: Morgan Stanley and Jefferies maintain Equal Weight and Hold respectively, Mizuho is Neutral, and KeyBanc downgraded from Overweight to Sector Weight in July 2026, while BMO Capital, Truist, and Argus remain constructive with Outperform and Buy ratings. The consensus therefore leans modestly bullish but is anchored by a large neutral bloc, consistent with a defensive utility where the debate is about rate-case timing and capital funding rather than a binary growth thesis. The target range of $68.00 to $86.00 is wide — a 26.5% spread from low to high — and the low end sits essentially at the current price, meaning the most bearish analyst sees no upside at all. The $86 high target would require multiple expansion toward the upper end of the historical PE band plus successful execution on Michigan rate relief and data-center load growth, while the $68 low target prices in margin compression from rising interest and depreciation expense, continued equity issuance dilution, and a flat regulatory outcome. The consensus EPS estimate of $5.21 (range $4.86 to $5.54) and revenue estimate of $10.47 billion (range $9.92 billion to $10.98 billion) frame the fundamental debate, and the fact that the stock trades near the low end of the target range after a 23.6-point relative underperformance versus SPY over the past year suggests the market is already discounting a fair amount of bad news — but with the consensus target only 10% above spot and the low target at parity, the risk/reward is balanced rather than compelling until the technical base near $62-$65 is confirmed and a positive regulatory catalyst emerges.
Bulls vs Bears: CMS Investment Factors
The bear case currently holds stronger near-term evidence: negative free cash flow of -$1.91 billion, 2.07x debt-to-equity, $362 million of equity issuance in a single quarter, and a 23.62-point relative underperformance gap versus the S&P 500 all point to a funding-constrained utility in a de-rating phase. The bull case rests on valuation support — 16.54x forward earnings, a 3.15% covered dividend, and a $75.83 consensus target implying 10.4% upside — plus a nascent one-month momentum reversal of +4.11% versus SPY's +1.22%. The single most important tension is whether Michigan rate relief and data-center-driven load growth can expand the rate base fast enough to outrun rising interest and depreciation expense; if allowed returns fail to keep pace, per-share earnings leverage stays capped and the dividend must be financed externally. Resolution of that regulatory question, more than any multiple re-rating, determines whether CMS is a value trap or a mean-reversion opportunity.
Bullish
- Deeply discounted relative to own history: At $68.70, CMS trades at 19.81x trailing and 16.54x forward earnings, with the forward multiple sitting near the middle of the 16x-18x utility peer band and the trailing multiple near the upper half of its own 14x-22x three-year range. The 8.09% one-year decline has been driven by earnings compression rather than multiple expansion, meaning the stock has not become more expensive even as it fell. The 2.30x price-to-book is within its 2.15x-2.69x historical band, implying the market is pricing a normal regulatory outcome, not distress.
- Analyst consensus implies 10.4% upside: Twelve analysts carry a consensus 'buy' with a mean rating of 2.27 and an average target of $75.83, roughly 10.4% above the current $68.70. The high target of $86.00 implies 25.2% upside and would require multiple expansion toward the top of the historical PE band plus successful Michigan rate relief. Even the low target of $68.00 sits essentially at spot, suggesting the downside is largely priced in.
- Well-covered 3.15% dividend with 61.9% payout: The 3.15% dividend yield is supported by a 61.9% payout ratio, comfortably covered by trailing earnings and consistent with a constructive Michigan regulatory compact. The 11.71% ROE and 12.54% trailing net margin confirm the regulated model generates adequate returns to sustain the distribution. Routine preferred dividend declarations reinforce the stable income profile that anchors the stock.
- Constructive one-month momentum off oversold lows: CMS is up 4.11% over the past month versus a 1.22% gain for SPY, producing a positive 2.89-point relative strength spread, and the latest session added 2.63% on the close. The stock is stabilizing around the $62-$65 zone after a 21.69% maximum drawdown, with the September trough near $62.60 acting as a secondary floor above the 52-week low of $62.29. This mean-reversion bounce suggests buyers are stepping in at depressed levels.
Bearish
- Negative free cash flow of -$1.91 billion: Trailing free cash flow is -$1.91 billion against Q2 capex of $967 million and Q1 capex of $1.039 billion, meaning the capital program is funded externally rather than from internal cash. Q2 operating cash flow of $622 million covered only about 64% of capex. This structural cash burn makes the dividend and growth dependent on continued access to credit markets.
- Equity dilution caps per-share leverage: CMS issued $362 million of common stock in Q2 2026, diluting shareholders to fund growth, with shares outstanding rising to 300.6 million from 298.5 million a year earlier. Q2 2026 EPS of $0.39 fell sharply from $0.66 a year ago, and net income dropped to $120 million from $201 million. Rising interest expense of $210 million and depreciation of $308 million are growing faster than allowed returns.
- Leverage and liquidity pressure: Debt-to-equity of 2.07x and a current ratio of 0.98 signal a balance sheet stretched by the capital program, with current liabilities essentially matching current assets. The 4.64x EV/Sales and 11.77x EV/EBITDA reflect a capital-intensive structure where leverage amplifies sensitivity to interest rates. Any credit-market tightening would directly constrain the funding model.
- Severe relative underperformance versus the market: CMS is down 8.09% over one year against a 15.53% gain for the S&P 500, a relative strength gap of -23.62 percentage points, and down 11.64% over six months versus SPY's +7.48%. The three-month change of -6.72% still lags SPY's +2.69% by 9.41 points. This persistent underperformance reflects a de-rating that has not yet reversed on a trend basis.
CMS Technical Analysis
CMS is in a sustained downtrend that has only recently begun to stabilize, with the stock down 8.09% over the past year and 11.64% over six months, badly trailing the S&P 500's 15.53% one-year gain for a relative strength gap of -23.62 percentage points. At $68.70, the shares sit at roughly 35.5% of the 52-week range of $62.29 to $80.36, having spent most of the past six months grinding lower from the April level near $77, which places the stock in recovery-from-lows territory rather than momentum-driven extension. The 21.69% maximum drawdown confirms this was a meaningful de-rating rather than a shallow pullback, and the positioning near the lower third of the range means the burden of proof remains on the bulls to establish a durable base. Recent momentum has turned constructive even as the longer-term trend remains negative: the stock is up 4.11% over the past month versus a 1.22% gain for SPY, producing a positive 2.89-point relative strength spread, while the three-month change of -6.72% still lags SPY's +2.69%. This divergence — positive one-month against negative one-year and three-month — is characteristic of a mean-reversion bounce off oversold conditions rather than a confirmed trend reversal, and the 2.63% single-day gain on the latest close suggests buyers are stepping in around the $63-$65 area. Key support rests at the 52-week low of $62.29, with the recent September trough near $62.60 acting as a secondary floor; a breakdown below that zone would signal a resumption of the downtrend and likely target new lows. Resistance sits at the 52-week high of $80.36, with intermediate supply likely around the $74-$77 area where the stock repeatedly failed in June and July. The beta of 0.314 is the critical risk-management input: CMS is roughly 69% less volatile than the market, which means position sizing can be larger for a given risk budget but also that the stock will not deliver sharp upside torque in a broad rally — this is a defensive, rate-sensitive instrument whose direction is driven more by Treasury yields and regulatory outcomes than by equity beta.
Beta
0.31
0.31x market volatility
Max Drawdown
-21.7%
Largest decline past year
52-Week Range
$62-$80
Price range past year
Annual Return
-6.7%
Cumulative gain past year
| Period | CMS Return | S&P 500 |
|---|---|---|
| 1m | +10.2% | -1.0% |
| 3m | -6.9% | +2.9% |
| 6m | -8.8% | +6.5% |
| 1y | -6.7% | +13.1% |
| ytd | -1.2% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CMS Fundamental Analysis
Revenue has been essentially flat to modestly declining: Q2 2026 revenue of $1.829 billion was down 0.49% year over year from $1.838 billion, following Q1 2026 revenue of $2.730 billion versus $2.447 billion in the prior-year quarter and Q4 2025 revenue of $2.233 billion versus $1.989 billion a year earlier. The quarterly pattern is highly seasonal — Q1 and Q4 carry the heaviest gas heating loads while Q2 and Q3 reflect milder weather and cooling demand — so the flat Q2 comparison is less alarming than it appears, but the absence of top-line growth still reflects a regulated model where revenue is largely a function of rate-case outcomes and weather rather than volume expansion. Segment data for the most recent period shows residential utility services at $908 million, commercial at $548 million, and industrial at $195 million, confirming that residential customers drive the majority of the revenue base and that the investment case hinges on Michigan rate relief and load growth rather than mix shift. Profitability is solid for a regulated utility: Q2 2026 net income was $120 million on a 6.56% net margin, with gross margin of 63.09% and operating margin of 20.22%, while the trailing twelve-month net margin of 12.54% and ROE of 11.71% are consistent with a constructive regulatory compact. The year-over-year comparison is less flattering — Q2 2025 net income was $201 million on an 10.94% net margin — and Q2 2026 EPS of $0.39 versus $0.66 a year ago reflects higher interest expense of $210 million and depreciation of $308 million as the rate base grows faster than allowed returns. The balance sheet is the pressure point: debt-to-equity of 2.07x, a current ratio of 0.98, and trailing free cash flow of -$1.91 billion against capital expenditure of $967 million in Q2 alone and $1.039 billion in Q1 mean the company is funding its capital program with debt and equity issuance rather than internal cash. Q2 2026 operating cash flow of $622 million covered only about 64% of capex, and the company issued $362 million of common stock in the quarter, diluting shareholders to fund growth — a structural feature of utility capital programs but one that caps per-share earnings leverage. The 3.15% dividend yield with a 61.9% payout ratio is well covered by earnings and remains the core support for the stock, but the negative FCF profile means the dividend is effectively financed alongside the capex program through external capital, which is sustainable only as long as credit markets and regulators cooperate.
Quarterly Revenue
$1.8B
2026-06
Revenue YoY Growth
-0.5%
YoY Comparison
Gross Margin
63.1%
Latest Quarter
Free Cash Flow
$-1.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CMS Overvalued?
Because CMS is profitable — Q2 2026 net income of $120 million and trailing EPS of roughly $3.47 implied by the 19.81x trailing PE on a $68.70 price — the PE ratio is the appropriate primary metric, and the gap between the 19.81x trailing and 16.54x forward multiple is the key signal. That 16.5% compression implies the market expects meaningful EPS growth, consistent with the consensus estimate of $5.21 for the forward period, though the reported quarterly EPS of $0.39 versus a $5.21 annual estimate highlights the seasonal skew and the reliance on second-half results. The forward multiple of 16.54x is reasonable in absolute terms for a regulated utility but must be judged against the sector and the company's own history. Against the broader utility sector, which typically trades in the 16x-18x forward PE range, CMS at 16.54x forward sits near the middle of the peer band rather than at a clear premium or discount, while its 2.30x price-to-book and 2.46x price-to-sales are unremarkable for a regulated name with an 11.71% ROE. The 11.77x EV/EBITDA and 4.64x EV/Sales are the more telling multiples given the capital-intensive structure, and the 3.48x PEG ratio signals that the earnings growth embedded in the forward estimate is not cheap relative to the multiple — a fair-to-full valuation for a low-beta, low-growth utility rather than a bargain. Historically, CMS has traded at a wide PE range: 13.96x in Q4 2023, 18.59x-19.91x through 2025, and a distorted 49.04x in the most recent Q2 2026 print due to the depressed quarterly EPS. The current 19.81x trailing PE sits near the upper end of the 2023-2025 band of roughly 14x-22x, while the 2.30x price-to-book is close to the 2.15x-2.69x range seen over the past three years, suggesting the market is pricing in a normal-to-slightly-optimistic regulatory outcome rather than distress. The stock's 8% one-year decline alongside a stable multiple implies the de-rating has come from earnings compression and rate-base dilution rather than multiple contraction, which means further downside would require a negative regulatory surprise rather than simple mean reversion.
PE
19.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 14x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the funding model. Trailing free cash flow of -$1.91 billion against Q2 capex of $967 million and Q1 capex of $1.039 billion means the capital program is externally financed, with Q2 operating cash flow of $622 million covering only about 64% of capex. Debt-to-equity of 2.07x and a current ratio of 0.98 leave little liquidity cushion, while Q2 2026 EPS of $0.39 versus $0.66 a year ago shows interest expense of $210 million and depreciation of $308 million consuming a growing share of earnings. The $362 million equity issuance in Q2 dilutes shareholders and structurally caps per-share earnings leverage, and revenue concentration in residential customers ($908 million of the segment base) ties results to Michigan rate outcomes and weather.
Market and competitive risks are dominated by valuation and rate sensitivity. At 19.81x trailing and 16.54x forward earnings, CMS sits mid-band versus utility peers but near the upper half of its own 14x-22x three-year range, leaving limited multiple expansion room; the 3.48x PEG ratio signals growth is not cheap. The 0.314 beta means the stock will not deliver sharp upside in a broad rally, and its direction is driven more by Treasury yields than equity momentum — a sustained rise in long rates would compress the relative appeal of a 3.15% yield. KeyBanc's July 2026 downgrade to Sector Weight and the neutral stances at Morgan Stanley, Jefferies, and Mizuho highlight that the consensus 'buy' is anchored by a large cautious bloc, and the absence of near-term catalysts beyond routine preferred dividend declarations leaves the stock exposed to sector rotation.
In a worst-case scenario, a negative Michigan rate-case outcome combines with rising interest expense and continued equity issuance to compress EPS below the $4.86 low analyst estimate, forcing the market to reprice the dividend as less secure. That chain would likely take the stock to the 52-week low of $62.29, or roughly -9.3% from the current $68.70, and a break below the September trough near $62.60 would signal a resumption of the downtrend toward new lows. The 21.69% maximum drawdown already experienced shows the de-rating can be meaningful, and the $68.00 analyst low target implies essentially zero upside. A more severe outcome — a credit-market tightening that constrains the external funding model — could extend losses toward the -21% drawdown magnitude, or roughly $54, though that requires a compounding of regulatory and funding shocks rather than a single disappointment.
FAQ
The most severe risk is financial: trailing free cash flow of -$1.91 billion against Q2 capex of $967 million means the capital program and dividend are funded externally, with 2.07x debt-to-equity and a 0.98 current ratio leaving little cushion. Second is dilution — $362 million of common stock issued in Q2 2026 capped per-share earnings, with Q2 EPS falling to $0.39 from $0.66 a year earlier. Third is regulatory: a negative Michigan rate-case outcome would limit allowed returns just as interest expense of $210 million and depreciation of $308 million are rising. Fourth is macro rate sensitivity — with a beta of 0.314, the stock's direction is driven more by Treasury yields than equity momentum, and rising long rates would compress the relative appeal of the 3.15% yield.
The base case carries 55% probability with a $70-$78 target range, assuming Michigan regulatory outcomes in line with precedent and EPS tracking near the $5.21 consensus, with the stock mean-reverting toward the $75.83 average target. The bull case at 20% probability targets $80-$86, requiring a favorable rate-case ruling, data-center load growth, and multiple expansion toward the top of the historical PE band. The bear case at 25% probability targets $62-$68, driven by an adverse rate ruling, EPS below the $4.86 low estimate, and a break of the $62.29 52-week low. The base case is most likely, with the key assumption being that the dividend remains covered and funding stays accessible.
CMS appears fairly valued rather than clearly overvalued or undervalued. The 16.54x forward PE sits mid-band versus the 16x-18x utility peer range, while the 19.81x trailing multiple is near the upper half of the stock's own 14x-22x three-year band, and the 2.30x price-to-book is within its 2.15x-2.69x historical range. The 3.48x PEG ratio signals that the earnings growth embedded in the forward estimate is not cheap relative to the multiple. The market appears to be pricing a normal-to-slightly-optimistic regulatory outcome rather than distress, with the 8% one-year decline driven by earnings compression rather than multiple contraction. Further downside would require a negative regulatory surprise rather than simple mean reversion.
From a risk/reward perspective, CMS is a balanced proposition rather than a compelling buy at $68.70. The consensus target of $75.83 implies 10.4% upside, and the 3.15% dividend is well covered at a 61.9% payout, but the $68.00 low analyst target sits at parity to spot, meaning the most bearish analyst sees no upside at all. The biggest downside risk is a negative Michigan rate-case outcome combined with continued equity issuance, which could take the stock to the $62.29 52-week low, roughly -9.3%. It is a reasonable buy for income-focused, risk-averse investors with a long horizon who want low-beta utility exposure, but growth-oriented investors should look elsewhere given flat revenue of -0.49% year over year and -$1.91 billion in trailing free cash flow.
CMS is better suited to long-term holding than short-term trading. Its beta of 0.314 means it lacks the volatility and momentum for tactical trading, and its direction is driven by Treasury yields and regulatory outcomes rather than technical momentum. The 3.15% dividend at a 61.9% payout rewards patient income investors, while the negative free cash flow and funding-dependent capital program require time for rate-base growth to translate into per-share earnings. The stock's 21.69% maximum drawdown and -23.62-point one-year relative strength gap versus SPY show that short-term positioning has been painful. A suggested minimum holding period of three to five years allows the regulatory compact and capital program to compound, consistent with a utility income allocation.